Mironid divulges new phosphodiesterase PDE4 activators
March 11, 2024
Mironid Ltd. has synthesized phosphodiesterase PDE4 activators reported to be useful for the treatment cancer, hyperparathyroidism, autosomal dominant polycystic kidney disease and autosomal recessive polycystic kidney disease.